Search Results - "Lanier, Ryan"

A deeper look at pain variability and its relationship with the placebo response: results from a randomized, double-blind, placebo-controlled clinical trial of naproxen in osteoarthritis of the knee by Treister, Roi, Honigman, Liat, Lawal, Oluwadolapo D., Lanier, Ryan K., Katz, Nathaniel P.

“…Previous studies have shown a robust correlation between variability of clinical pain scores and responsiveness to placebo (but not active drug) in pain…”
Get full text

Placebo Response Reduction and Accurate Pain Reporting Training Reduces Placebo Responses in a Clinical Trial on Chronic Low Back Pain: Results From a Comparison to the Literature by Erpelding, Nathalie, Evans, Kathryn, Lanier, Ryan K., Elder, Harrison, Katz, Nathaniel P.

“…OBJECTIVE:A literature review was conducted to compare placebo responses in a recent trial—which implemented an accurate pain reporting (APR) and placebo…”
Get full text

Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs by Zia, Farah Z., Baumann, Michael H., Belouin, Sean J., Dworkin, Robert H., Ghauri, Majid H., Hendricks, Peter S., Henningfield, Jack E., Lanier, Ryan K., Ross, Stephen, Berger, Ann

“…Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States…”
Get full text

Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study by As-Sanie, Sawsan, Soliman, Ahmed M., Evans, Kathryn, Erpelding, Nathalie, Lanier, Ryan K., Katz, Nathaniel P.

“…To determine the prevalence and pattern of opioid use in endometriosis and the characteristics of patients prescribed an opioid using medical insurance claims…”
Get full text

REL-1017 (esmethadone; d-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats by Henningfield, Jack, Gauvin, David, Bifari, Francesco, Fant, Reginald, Shram, Megan, Buchhalter, August, Ashworth, Judy, Lanier, Ryan, Pappagallo, Marco, Inturrisi, Charles, Folli, Franco, Traversa, Sergio, Manfredi, Paolo L.

“…REL-1017 (esmethadone, d -methadone) is the opioid-inactive d-isomer of racemic d,l -methadone. REL-1017 may exert antidepressant effects via uncompetitive N…”
Get full text

Assessment of the abuse potential and benefits of kratom and its mitragynine alkaloids: Implications for regulation by Lanier, Ryan K, Fant, Reginald Vane, Cone, Edward, Henningfield, Jack

Get full text

Nicotine-Like Behavioral Effects of the Minor Tobacco Alkaloids Nornicotine, Anabasine, and Anatabine in Male Rodents by Caine, S. Barak, Collins, Gregory T, Thomsen, Morgane, Wright, Curtis, Lanier, Ryan K, Mello, Nancy K

“…Tobacco use is associated with lethal diseases in an estimated 440,000 persons in the United States each year (Centers for Disease Control and Prevention,…”
Get full text

Effects of an anatabine and yerba maté lozenge on craving in smokeless tobacco users and heavy smokers by Lanier, Ryan K, Cohen, Amy, Gibson, Kainen, Varga, Maria, Wright, Curtis

Get full text

Assessment of potentially abuse-related events in two phase 3 studies of NKTR-181, a novel opioid analgesic, using the MADDERS® system (Misuse, Abuse, and Diversion Drug Event Reporting System) by Lanier, Ryan K., Henningfield, Jack E., Gudin, Jeffrey, Rauck, Richard, Elder, Harrison, Erpelding, Nathalie, Treister, Roi, Gimbel, Joseph, Tagliaferri, Mary, Doberstein, Stephen K., Di Fonzo, Carlo J., Lu, Lin, Siddhanti, Suresh, Katz, Nathaniel P.

“…Objective: To prospectively evaluate the abuse potential of NKTR-181, a novel opioid analgesic, in two phase 3 clinical trials using a newly developed…”
Get full text

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users by Shram, Megan J., Henningfield, Jack E., Apseloff, Glen, Gorodetzky, Charles W., De Martin, Sara, Vocci, Frank L., Sapienza, Frank L., Kosten, Thomas R., Huston, Jeff, Buchhalter, August, Ashworth, Judy, Lanier, Ryan, Folli, Franco, Mattarei, Andrea, Guidetti, Clotilde, Comai, Stefano, O’Gorman, Cedric, Traversa, Sergio, Inturrisi, Charles E., Manfredi, Paolo L., Pappagallo, Marco

“…Esmethadone (REL-1017) is the opioid-inactive dextro-isomer of methadone and a low-affinity, low-potency uncompetitive NMDA receptor antagonist. In a Phase 2,…”
Get full text

Discriminative stimulus effects of tramadol in humans by Duke, Angela N, Bigelow, George E, Lanier, Ryan K, Strain, Eric C

“…Tramadol is an unscheduled atypical analgesic that acts as an agonist at μ-opioid receptors and inhibits monoamine reuptake. Tramadol can suppress opioid…”
Get more information

Physical dependence potential of daily tramadol dosing in humans by Lanier, Ryan K., Lofwall, Michelle R., Mintzer, Miriam Z., Bigelow, George E., Strain, Eric C.

“…Rationale Tramadol is an atypical, mixed-mechanism analgesic involving both opioid and catecholamine processes that appears to have low abuse potential and may…”
Get full text

Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers by Mintzer, Miriam Z, Lanier, Ryan K, Lofwall, Michelle R, Bigelow, George E, Strain, Eric C

“…Abstract Tramadol is an atypical, mixed mechanism analgesic used to treat moderate to severe pain. Based on evidence that tramadol has relatively low abuse…”
Get full text

Effects of anatabine at relevant human nicotinic receptor subtypes in vitro and on craving and C-reactive protein in heavy smokers by Lanier, Ryan K, Cohen, Amy E, Loescher, Jane L, Gibson, Kainen D, Varga, Maria, Wright, Curtis

Get full text

Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario and McMaster Universities Osteoarthritis Index Pain Scales by Ross, Edgar, Katz, Nathaniel P., Conaghan, Philip G., Kivitz, Alan, Turk, Dennis C., Spitzer, Andrew I., Jones, Deryk G., Lanier, Ryan K., Cinar, Amy, Lufkin, Joelle, Kelley, Scott D.

“…Introduction A phase 3 randomized controlled study comparing triamcinolone acetonide extended-release (TA-ER) to conventional TA crystalline suspension (TAcs)…”
Get full text

Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial by Schmeltz, Lowell R, Blevins, Thomas C, Aronoff, Stephen L, Ozer, Kerem, Leffert, Jonathan D, Goldberg, Marc A, Horowitz, Barry S, Bertenshaw, Richard H, Troya, Pedro, Cohen, Amy E, Lanier, Ryan K, Wright, Curtis

“…Context: Hashimoto's thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported…”
Get full text

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone by Tompkins, David Andrew, Lanier, Ryan K., Harrison, Joseph A., Strain, Eric C., Bigelow, George E.

“…Rationale Prescription opioid abuse has risen dramatically in the United States as clinicians have increased opioid prescribing for alleviation of both acute…”
Get full text

Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers by Bauer, Kenneth A., MD, Gerson, William, MD, Wright, Curtis, MD, MPH, Wang, Jianyuan, PhD, McNicol, Ewan, MS, Lanier, Ryan K., PhD, Kramer, William, PhD, Carr, Daniel B., MD

“…Abstract Study Objective To assess platelet function and safety following single-dose administration of a novel formulation of intravenous (IV) diclofenac…”
Get full text

Effects of a Facial Cream Containing the Minor Alkaloid Anatabine on Improving the Appearance of the Skin in Mild to Moderate Rosacea: An Open-Label Case Series Study by Lanier, Ryan K., Cohen, Amy E., Weinkle, Susan H.

“…Background: Current medical and scientific research indicates that rosacea, a chronic and often debilitating skin condition that primarily affects the central…”
Get full text

Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation by Lanier, Ryan K., Umbricht, Annie, Harrison, Joseph A., Nuwayser, Elie S., Bigelow, George E.

“…Rationale Managed withdrawal (i.e., detoxification) from opioid dependence is a widespread clinical procedure that is a necessary step for those pursuing…”
Get full text